These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21192844)

  • 21. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
    Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
    Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
    Korantzis I; Kalogeras KT; Papaxoinis G; Kotoula V; Koutras A; Soupos N; Papakostas P; Dionysopoulos D; Samantas E; Christodoulou C; Linardou H; Pectasides D; Fountzilas G
    Anticancer Res; 2012 Oct; 32(10):4569-80. PubMed ID: 23060588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
    Sato N; Sano M; Tabei T; Asaga T; Ando J; Fujii H; Yamamoto N; Kurosumi M; Inoue K; Kimura M
    Breast Cancer; 2006; 13(2):166-71. PubMed ID: 16755112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer].
    Wu SK; Ma Y; Meng XY; Sun B; Wang T; Zhang SH; Jiang ZF; Song ST
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):764-9. PubMed ID: 23291071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR in 94 breast cancer patients with a follow up of 9 years.
    Pierga JY; Bidard FC; Denis MG; de Cremoux P
    Mol Oncol; 2007 Dec; 1(3):267-8. PubMed ID: 19383302
    [No Abstract]   [Full Text] [Related]  

  • 26. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
    Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
    Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
    Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
    Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
    Georgoulias V; Apostolaki S; Bozionelou V; Politaki E; Perraki M; Georgoulia N; Kalbakis K; Kotsakis A; Xyrafas A; Agelaki S; Mavroudis D
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1217-25. PubMed ID: 25344760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
    Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
    Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
    Li J; Hu YM; Du YJ; Zhu LR; Qian H; Wu Y; Shi WL
    BMC Cancer; 2014 Nov; 14():848. PubMed ID: 25410981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
    Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
    Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction.
    Noguchi S; Aihara T; Nakamori S; Motomura K; Inaji H; Imaoka S; Koyama H
    Cancer; 1994 Sep; 74(5):1595-600. PubMed ID: 7520351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
    Stathopoulos GP; Tsavdaridis D; Malamos NA; Rigatos SK; Kosmas Ch; Pergantas N; Stathopoulos JG; Xynotroulas J
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):487-91. PubMed ID: 15868147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
    Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V
    Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy.
    Sabbatini R; Federico M; Morselli M; Depenni R; Cagossi K; Luppi M; Torelli G; Silingardi V
    J Clin Oncol; 2000 May; 18(9):1914-20. PubMed ID: 10784632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.